Laurus Labs completes US FDA inspection at Unit 2, Visakhapatnam

Laurus Labs Ltd. (Laurus BSE: 540222, NSE: Lauruslabs, ISIN: INE947Q01010), a leading research and development driven pharmaceutical company has completed the US Food and Drug Administration (USFDA) inspection of its Unit - 2 (FDF&API integrated facility), located at APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh, with two observations which are procedural in nature.

This is a product pre-approval audit by USFDA, and no data integrity issues were observed in the inspection. The inspection was carried out from 04 November, 2019 - 08 November, 2019.

Shares of Laurus Labs Ltd was last trading in BSE at Rs.366.9 as compared to the previous close of Rs. 369.8. The total number of shares traded during the day was 4567 in over 255 trades.

The stock hit an intraday high of Rs. 381.95 and intraday low of 364.4. The net turnover during the day was Rs. 1687565.

Source : Equity Bulls

Keywords